ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Aspirin

Also written as “dabigatran with ASA”, “ASA” and “Acetylsalicylic acid (Aspirin, BAY1019036)”.

Its studies are mostly in Coronary Artery Disease · Cardiovascular Diseases · Common Cold · Thrombosis · Peptic Ulcer, led by 28 companies.

Drug pageAspirin: every studyMany companies study it; this page follows only the 70 they lead. All 675 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Dec 15, 200970 company-led studies, 3 open or runningNext primary completion: Mar 10, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bayerits history only211 open or runningphase 4since Dec 15, 2009Jul 12, 2007Mar 10, 2027phase 1 · NCT07652723
Boehringer Ingelheimits history only60 open or runningphase 4since Aug 10, 2005Aug 10, 2005none ahead
Bristol-Myers Squibbits history only50 open or runningphase 1since Jul 8, 2009Jul 8, 2009none ahead
Abbottits history only30 open or runningphase 3since Feb 21, 2008Feb 21, 2008none ahead
Boston Scientificits history only30 open or runningphase 4since May 1, 2012Dec 21, 2011none ahead
Johnson & Johnsonits history only30 open or runningphase 4since Dec 2, 2005Dec 2, 2005none ahead
Aralez Pharmaceuticalsits history only20 open or runningphase 1since Feb 27, 2007Feb 27, 2007none ahead
Astellas Pharmaits history only20 open or runningphase 4since May 26, 2016Aug 1, 2011none ahead
Biogenits history only20 open or runningphase 4since Mar 14, 2014Jan 20, 2011none ahead
Chong Kun Dang Pharmaceuticalits history only20 open or runningphase 1since Dec 20, 2010Dec 20, 2010none ahead
Rhoshan Pharmaceuticals10 open or runningphase 1since Dec 18, 2025Dec 18, 2025none ahead

Also a collaborator on its studies: Cardialysis, Terumo and ClinLogix.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Rhoshan Pharmaceuticals only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 18, 2025First study: phase 1 study in HealthyFirst studyNCT07323680 · 40 enrolled · Czechia

TargetBeta

PTGS1 →PTGS2 →read by rule
“Cyclooxygenase inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
AcetaminophenruleJohnson & Johnsonphase 4136
IbuprofenrulePfizerphase 4113
dexketoprofenruleMenarini Groupphase 48
SulfasalazineruleBristol-Myers Squibbphase 47
dexibuprofenruleaponia-laboratories-incphase 46
BenzydamineruleAngelini Pharmaphase 44
DipyroneruleHypera Pharmaphase 44
PiroxicamruleTaisho Pharmaceuticalphase 44
FlurbiprofenruleGlaxoSmithKlinephase 312

Studies

The one study Rhoshan Pharmaceuticals leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07323680Healthy · Czechia1CompletedJul 7, 202540

How it is read

Names in the registry

  • “Aspirin”, 25 entries
  • “dabigatran with ASA”, 6 entries
  • “ASA”, 5 entries
  • “Acetylsalicylic acid (Aspirin, BAY1019036)”, 5 entries
  • “Acetylsalicylic acid (Aspirin, BAYE4465)”, 5 entries

Codes read as this program: BAY1019036.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.